Blaze Bioscience Inc. Announces Two Poster Presentations at AACR-SNMMI Conference and Award of NCI SBIR Contract Advancing Tumor PaintTM Technology
Published: Feb 27, 2013
Blaze Bioscience, Inc., a biotechnology company dedicated to developing innovative products to improve the lives of cancer patients, announced today that two posters on aspects of the development of Tumor PaintTM technology will be presented at the American Association of Cancer Research and Society of Nuclear Medicine and Molecular Imaging (AACR-SNMMI) joint conference. These poster presentations are additional recognition of the scientific work that started in the laboratory of Blaze Bioscience co-founder Dr. Jim Olson of the Fred Hutchinson Cancer Research Center and is being continued at Blaze.